Skip to search formSkip to main contentSkip to account menu

XL880

Known as: XL 880, XL-880, XL880 cpd 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

GSK 1363089Organic Chemicals
foretinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Abstract 3042: LY2801653: An orally bioavailable MET kinase inhibitor with inhibitory activity against the oncoproteins ROS1 and MKNK1/2.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Under normal conditions MET receptor activation… 
2009
2009
State-ofthe-art treatment of metastatic renal cell carcinoma
s+%26+Virtual+Meeting/Abstracts?&vmview=abst_ detail_view&confID=47&abstractID=33225; cited January 19, 2009] 47. Rixe O… 
2007
2007
Gateways to clinical trials.
(-)-Epigallocatechin gallate, [188Re]-P2045, 12B75, 89-12; Abacavir sulfate/lamivudine, Abatacept, Abiraterone acetate, ABT-869… 
2006
2006
A phase I study of a novel spectrum selective kinase inhibitor (SSKI), XL880, administered orally in patients (pts) with advanced solid tumors (STs).
3041 Background: XL880 is a sub-nM inhibitor of the hepatocyte growth factor receptor (Met) and vascular endothelial growth… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)